Method and kit for the detection of genes associated with PIK3CA mutation and involved in PI3K/AKT pathway activation in the ER-postitive and HER2-positive subtypes with clinical implications
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 12, 2013
Grant Date -
Feb 17, 2011
app pub date -
Aug 20, 2010
filing date -
Feb 21, 2008
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
A method to determine the clinical outcome of breast tumor affecting a patient if treated with an antitumoral agent against breast tumor. The method includes the step of assaying a sample of a breast tumor from the patient for an expression level of selected genes, by contacting mRNA sequences from the cells of this breast tumor with a set of more than 3 nucleotide sequences related to human mutated PIK3CA.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully